AR and prostate cancer: demonstrated that MALAT1/SF2/AR‐v7 axis confers enzalutamide resistance in prostate cancer and the MALAT1‐targeting siRNA suppresses enzalutamide‐resistant prostate cancer growth.[44] Targeted delivery of MALAT1 siRNA by nanocomplex also improves the sensitivity of glioblastoma cells to temozolomide.[45] Previously, Li et al.